non-myeloablative 非清髓性 ; 移植物抗宿主病
non-myeloablative therapy 非清髓性治疗
non-myeloablative conditioning 非清髓性预处理
myeloablative conditioning regimen 清髓性预处理方案
non-myeloablative allogeneic stem cell transplantation 异基因造血干细胞移植
myeloablative bone marrow transplantation 清髓性骨髓移植
non-myeloablative pretreatment conditioning 非清髓性预处理
non-myeloablative stem cell transplantation 非清髓造血干细胞移植
This report will evaluate the efficacy and safety of combination of Gleevec and myeloablative allogenetic hemapoieticstem cell transplantation for the treatment of 9 CML patients.
本文将对格列卫联合清髓性异基因造血干细胞移植治疗9例慢性、加速以及急变期CML患者的有效性和安全性进行评估。
参考来源 - 格列卫联合清髓性异基因造血干细胞移植治疗慢性粒细胞白血病的临床观察·2,447,543篇论文数据，部分数据来源于NoteExpress
Myeloablative regiment and cytomegalovirus infection were the main risk factors of HC, indicated by multiplicity analysis.
多因素分析提示，清髓性预处理、巨细胞病毒感染是移植后出血性膀胱炎发生的相关因素。
The aim is to exploit the graft-versus-tumor (GVT) effect seen after allografting without the toxicities of myeloablative conditioning.
其目的是利用移植物抗肿瘤（ GVT ）作用后可见异体没有毒性髓空调。
Post non myeloablative allogeneic stem cell transplantation (NST) patients usually received DLI one times a month, consecutively 1 ~ 4 times.
非去髓性异基因干细胞移植(nst)患者通常在移植后每月输注1次，连续1 ~ 4次。
应用推荐